<?xml version='1.0' encoding='utf-8'?>
<document id="26948084"><sentence text="Assessment of Drug-Drug Interaction between Warfarin and Aprepitant and Its Effects on PT-INR of Patients Receiving Anticancer Chemotherapy."><entity charOffset="44-52" id="DDI-PubMed.26948084.s1.e0" text="Warfarin" /><entity charOffset="57-67" id="DDI-PubMed.26948084.s1.e1" text="Aprepitant" /><pair ddi="false" e1="DDI-PubMed.26948084.s1.e0" e2="DDI-PubMed.26948084.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26948084.s1.e0" e2="DDI-PubMed.26948084.s1.e1" /></sentence><sentence text="Aprepitant is a known inducer of CYP2C9, the main warfarin-metabolizing enzyme" /><sentence text=" Consequently, co-administration of these two drugs may result in reduction of the anticoagulation activity of warfarin" /><sentence text=" However, the nature and degree of time-dependent changes in prothrombin time international normalized ratio (PT-INR) after aprepitant and warfarin co-treatment in patients receiving anticancer chemotherapy has not been elucidated"><entity charOffset="124-134" id="DDI-PubMed.26948084.s4.e0" text="aprepitant" /></sentence><sentence text=" We retrospectively examined the changes in warfarin dose, PT-INR, and warfarin sensitivity index (WSI; average of PT-INR value/average of daily warfarin dose) during four weeks, i" /><sentence text="e" /><sentence text=", one week before and three weeks after aprepitant administration" /><sentence text=" The mean and standard deviation values of WSI for one week before and one, two, and three weeks after the beginning of aprepitant administration were 0"><entity charOffset="120-130" id="DDI-PubMed.26948084.s8.e0" text="aprepitant" /></sentence><sentence text="51±0" /><sentence text="22 (1" /><sentence text="00, n=34), 0" /><sentence text="74±0" /><sentence text="30 (1" /><sentence text="53±0" /><sentence text="59, n=30), 0" /><sentence text="38±0" /><sentence text="15 (0" /><sentence text="82±0" /><sentence text="22, n=28), and 0" /><sentence text="46±0" /><sentence text="29 (0" /><sentence text="87±0" /><sentence text="23, n=24), respectively" /><sentence text=" Values in parentheses represent relative changes versus WSI of one week before and number of subjects" /><sentence text=" Although the mean value of WSI significantly increased one week after aprepitant administration compared to that at one week before the administration, it in turn significantly decreased two weeks after compared to one week before (paired t-test, p&lt;0"><entity charOffset="71-81" id="DDI-PubMed.26948084.s25.e0" text="aprepitant" /></sentence><sentence text="05 after Bonferoni correction)" /><sentence text=" In patients taking warfarin, PT-INR should be carefully monitored for at least two weeks after the beginning of aprepitant administration because it may fluctuate with both aprepitant and chemotherapy during this period"><entity charOffset="113-123" id="DDI-PubMed.26948084.s27.e0" text="aprepitant" /><entity charOffset="174-184" id="DDI-PubMed.26948084.s27.e1" text="aprepitant" /><pair ddi="false" e1="DDI-PubMed.26948084.s27.e0" e2="DDI-PubMed.26948084.s27.e0" /><pair ddi="false" e1="DDI-PubMed.26948084.s27.e0" e2="DDI-PubMed.26948084.s27.e1" /></sentence><sentence text=" " /></document>